Friday 16 October 2026 Export ALEC’s income statement to Excel — free account

Alector, Inc.

Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.

1.84 0.07 −3.66%

Follow ALEC

Alert me

Market cap: $213.3M
P/E: 0.0×
Fwd P/E: −1.9×
Dividend yield: —
F-score: 1/9
Altman Z: −5.15
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	5	—	1	5	1	—	3	—	—	3	—

Insider Ownership 25.95%

Capital & Financial Ratios $m

Market Cap 213.27

Revenue 13.86

Net Income (117.85)

Free Cash Flow (158.39)

Net Debt (162.95)

Current Ratio 5.26

Debt/Equity (0.99)

P/E ratio 0.00

Fwd P/E (1.91)

P/S ratio 14.76

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 72.53%

Next Y EPS Growth (118.98%)

Next Y revenue growth 10.33%

Next 5Y EPS Growth 20.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 64.27%

10-year low 10-year high

EV/Sales against its own 10 years 38.83%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	549	413	256	173
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	566	425	266	180

	2023	2024	2025	Q'26
Payables	4	2	2	2
ST’ Debt	—	—	0	10
Other	39	49	11	—
	178	125	70	34

Compound Annual Growth %

	10y	5y	3y
Sales	—	(0.05%)	(46.00%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(35.17%)	(47.72%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	3	—	—	—
’25	4	8	3	6	21
’24	16	15	15	54	101
’23	17	56	9	15	97
’22	24	80	15	14	134
’21	4	7	182	14	207
’20	7	3	6	5	21

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(34)	—	—	—
’25	(61)	(49)	(33)	(42)	(184)
’24	(61)	(63)	(51)	(55)	(230)
’23	(49)	(43)	(47)	(46)	(184)
’22	135	(57)	(49)	(49)	(20)
’21	(53)	(45)	445	(49)	299
’20	(32)	(46)	(41)	(48)	(167)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(34)	—	—	—
’25	(61)	(49)	(33)	(42)	(184)
’24	(62)	(63)	(51)	(55)	(231)
’23	(50)	(44)	(46)	(46)	(187)
’22	134	(58)	(51)	(50)	(24)
’21	(54)	(45)	444	(50)	295
’20	(36)	(46)	(41)	(48)	(172)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.21)	(0.21)	—	—	—
’25	(0.41)	(0.30)	(0.34)	(0.34)	(1.39)
’24	(0.38)	(0.40)	(0.43)	(0.02)	(1.23)
’23	(0.55)	0.02	(0.53)	(0.49)	(1.56)
’22	(0.54)	0.12	(0.56)	(0.63)	(1.62)
’21	(0.66)	(0.69)	1.49	(0.68)	(0.45)
’20	(0.53)	(0.58)	(0.67)	(0.66)	(2.45)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	13.64	9.12	14.66	6.85	3.66	1.68	0.87	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	27.00	35.93	43.32	21.26	9.86	8.90	3.40
People
People	Employees	—	—	78	121	171	208	273	244	238	103
	Revenue/emp, $m	0.00	0.00	0.35	0.18	0.12	1.00	0.49	0.40	0.42	0.20
Income, $m
Income, $m	Revenue	0	4	28	21	21	207	134	97	101	21
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(15)	(32)	(52)	(105)	(190)	(36)	(130)	(125)	(119)	(143)
	EBT margin, %	(3,632.21)	(869.61)	(188.78)	(496.65)	(901.64)	(17.54)	(97.33)	(128.97)	(118.26)	(678.36)
	Net income	(15)	(32)	(52)	(105)	(190)	(36)	(133)	(130)	(119)	(143)
	Depreciation	0	1	1	6	8	10	7	(6)	(6)	3
Per share, $
Per share, $	Revenue	0.06	0.41	2.45	0.34	0.27	2.58	1.62	1.16	1.04	0.20
	Earnings	(2.11)	(3.55)	(4.62)	(1.71)	(2.45)	(0.45)	(1.62)	(1.56)	(1.23)	(1.39)
	Cash flow	(1.81)	(1.94)	11.28	(1.61)	(2.14)	3.71	(0.25)	(2.20)	(2.38)	(1.79)
	Capex	(0.31)	(0.09)	(0.17)	(0.25)	(0.06)	(0.04)	(0.05)	(0.03)	(0.01)	0.00
	Free cash flow	(2.13)	(2.03)	11.11	(1.86)	(2.21)	3.67	(0.30)	(2.23)	(2.39)	(1.79)
	Book value	0.00	2.78	10.01	3.15	3.44	3.74	2.60	1.60	1.31	0.30
	Shares, m	7	9	11	62	78	80	82	84	97	103
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	7.67	7.67	7.67	50.13	55.76	8.02	5.62	6.89	1.82	7.64
	P/B	0.00	0.00	0.00	5.46	4.40	5.52	3.50	4.99	1.44	5.24
	EV/Sales	(2.82)	(2.82)	(2.82)	35.75	38.60	4.70	0.61	1.65	(2.12)	(4.07)
	EV/FCF	(0.62)	(0.62)	(0.62)	(6.62)	(4.74)	3.29	(3.31)	(0.86)	0.92	0.47
Cash, $m
Cash, $m	Operating cash flow	(13)	(18)	127	(99)	(167)	299	(20)	(184)	(230)	(184)
	Capex	(2)	(1)	(2)	(15)	(5)	(3)	(4)	(2)	(1)	0
	Free cash flow	(15)	(19)	126	(115)	(172)	295	(24)	(187)	(231)	(184)
Balance, $m
Balance, $m	Working capital	50	206	245	295	353	610	633	388	300	197
	Total debt	—	—	—	48	51	48	43	—	9	10
	Net debt	(51)	(32)	(290)	(305)	(362)	(688)	(670)	(549)	(404)	(246)
	Shareholders’ equity	—	25	113	195	268	301	214	134	127	31
Returns, %
Returns, %	ROA	(12.80)	(27.52)	(19.19)	(28.86)	(41.80)	(5.58)	(16.64)	(18.50)	(21.84)	(37.54)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	39.28	84.43	69.93	(216.52)	(82.30)	(12.79)	(51.75)	(74.81)	(91.24)	(181.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
PLX Protalix BioTherapeutics, Inc.	$217.5M	11.4×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
ALEC Alector, Inc.	$213.3M	— (loss-making)	— (loss-making)	−57.84% (below 0%: shrinking)	n/m	+30.19% (above 0%: growing)	100.00%	(734.73%)
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
Median of peers	$215.2M	—	—	+22.96%	—	+3.71%	100.00%	0.00%

All 614 Biotechnology stocks →

Alector, Inc. (ALEC) key facts

Concern: Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
Concern: Alector, Inc. reported a net loss of $142.9 million, or a loss of $1.39 per share, for fiscal 2025.
Alector, Inc. (ALEC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALEC traded at $1.84, a market capitalization of $213.3 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 14.8× sales.
Return on equity was −181.6% and debt-to-equity -0.99.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −5.15 (distress zone) for fiscal 2025.